{
    "clinical_study": {
        "@rank": "72172", 
        "acronym": "POORTOR", 
        "arm_group": {
            "arm_group_label": "Everolimus", 
            "arm_group_type": "Experimental", 
            "description": "Everolimus will be administred per os every day at the same hour immediatly after a meal with a glass of water 10 mg (1 tablet of 10 mg)"
        }, 
        "brief_summary": {
            "textblock": "It is a an open label, multicentric, phase II study assessing the efficacy of everolimus\n      (given per os) as a first line treatment in kidney cancer of bad prognosis.\n\n      90 patients will be included (anticipated). The treatment by everolimus will continue until\n      progression, significant toxicity or withdraw of consent"
        }, 
        "brief_title": "Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer", 
        "completion_date": {
            "#text": "January 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Kidney Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Renal Cell", 
                "Kidney Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Metastatic kidney cancer, regardless of histology (except Bellini carcinomas), with\n             measurable or evaluable disease\n\n          2. Age >= 18 years\n\n          3. With Karnofsky \u2265 60\n\n          4. Without prior treatment for metastatic cancer (chemotherapy, targeted therapy, or\n             mTOR inhibitor)\n\n          5. Bad prognosis, defined as follows: at least three of the following six criteria of\n             poor prognosis:\n\n               -  Karnofski <80\n\n               -  LDH> 1.5 ULN\n\n               -  hemoglobin <LLN\n\n               -  corrected calcium> 2.5 mmol / l (10 mg / dl)\n\n               -  Time frame between initial diagnostic and treatment <1 year\n\n               -  More than one metastatic site\n\n          6. medullary function: neutrophils \u2265 1.5 x 109 / L, Platelets \u2265 100 x 109 / L, Hb> 8g/dL\n\n          7. Hepatic function: bilirubin: \u2264 1.5 x ULN, ALT and AST \u2264 2.5x ULN in the absence of\n             hepatic metastasis \u2264 5x ULN if hepatic metastasis documented\n\n          8. Renal function: creatinine <1.5 x ULN\n\n          9. Life expectancy> 3 months,\n\n         10. Patient signed informed consent and agreeing to comply with the requirements of the\n             trial\n\n        Exclusion Criteria:\n\n          1. Previous treatment with chemotherapy, targeted therapy, or mTOR inhibitor\n\n          2. Previous radiotherapy in the last 2 weeks\n\n          3. Chronic treatment with corticoids or immunosuppressive agents except substitutive\n             opotherap.. A washout period of at least 8 days must be respected before the patient\n             inclusion.\n\n          4. Patients with brain metastases untreated or uncontrolled by prior treatment. The\n             non-progression of the metastases must be proved by comparing two brain scans\n             separated by a minimum interval of 6 weeks.\n\n          5. Active bleeding\n\n          6. Patient with positive serology HBs (Ag HBs (+) and AC anti-HBc (+)\n\n          7. Hypersensitivity to everolimus, sirolimus, to other rapamycin derivatives or to any\n             of the excipients\n\n          8. Severe or uncontrolled medical pathology:\n\n               -  unstable angor, symptomatic heart failure, myocardial infarction \u2264 6 months\n                  before randomization, severe rhythm disorder,\n\n               -  Uncontrolled diabetes with glycaemia> 1.5X ULN.\n\n               -  Active or uncontrolled infection.\n\n               -  cirrhosis or chronic active hepatitis,\n\n               -  severe alteration in lung function (> 50% decrease in FEV or vital capacity)\n\n          9. Other cancer within the past 3 years, with the exception of basal cell carcinoma and\n             carcinoma in situ of the cervix\n\n         10. Pregnant or lactating woman, and adults refusing an effective contraceptive method\n\n         11. Participation in another clinical trial with an investigational drug\n\n         12. Refusal of the patient to comply with the rules of the clinical trial\n\n         13. Person deprived of liberty or person under guardianship, inability to submit to\n             medical treatment test for geographical, social or psychological reasons."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01888042", 
            "org_study_id": "2011-00979-14", 
            "secondary_id": "2011/1733"
        }, 
        "intervention": {
            "arm_group_label": "Everolimus", 
            "description": "10 mg (1 tablet of 10 mg)", 
            "intervention_name": "Everolimus", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 25, 2013", 
        "location": {
            "contact": {
                "email": "bernard.escudier@gustaveroussy.fr", 
                "last_name": "Bernard ESCUDIER, MD", 
                "phone": "0142445410", 
                "phone_ext": "+33"
            }, 
            "facility": {
                "address": {
                    "city": "Villejuif", 
                    "country": "France", 
                    "state": "Val de Marne", 
                    "zip": "94805"
                }, 
                "name": "Gustave Roussy"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study Assessing Everolimus as Fist Line Treatment in Patients With Metstatic Kidney Cancer of Bad Prognosis", 
        "overall_contact": {
            "email": "bernard.escudier@gustaveroussy.fr", 
            "last_name": "Bernard ESCUDIER, MD", 
            "phone": "0142115410", 
            "phone_ext": "+33"
        }, 
        "overall_contact_backup": {
            "email": "valerie.mairot@gustaveroussy.fr", 
            "last_name": "Val\u00e9rie MAIROT", 
            "phone": "0142116643", 
            "phone_ext": "+33"
        }, 
        "overall_official": {
            "affiliation": "Gustave Roussy, Cancer Campus, Grand Paris", 
            "last_name": "Bernard ESCUDIER", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France: Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Overall Survival (OS)", 
            "safety_issue": "Yes", 
            "time_frame": "From inclusion to progression, significant toxicity  or death wichever come first up to 56 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01888042"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Response rate based on RECIST 1.1 criteria", 
                "measure": "Response rate", 
                "safety_issue": "No", 
                "time_frame": "From inclusion to progression, significant toxicity or death whichever come first up to 56 months"
            }, 
            {
                "measure": "Toxicity of Everolimus", 
                "safety_issue": "Yes", 
                "time_frame": "From inclusion to progression, significant toxicity or death whichever come first up to 56 months"
            }, 
            {
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "From inclusion to progression, significant toxicity or death whichever come first up to 56 months"
            }
        ], 
        "source": "Gustave Roussy, Cancer Campus, Grand Paris", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gustave Roussy, Cancer Campus, Grand Paris", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}